Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2004

View Archived Issues

Eisai investigating novel AMPA receptor antagonists

Analgesic efficacy of tetrodotoxin in refractory cancer pain

Benefits of Permixon in patients with prostatic disorders

Analysis suggesting MC-1 effective in diabetic patients with hypertension supports MC-4232 program

Human growth hormone found effective against wasting in HIV patients receiving HAART

First double-blind evidence for efficacy of topical clonazepam in stomatodynia

Dual PPARalpha/gamma agonists under investigation for metabolic syndromes at Dr. Reddy

Novel potent inhibitors of palmitoyl-CoA oxidation

Update on novel antitumor drugs under development by Salmedix

Amgen returns epratuzumab rights to Immunomedics

Approval for new formulation of Protonix I.V.

Phase III MabThera trial meets primary endpoints two years early

Acambis suspends enrollment in ACAM-2000 phase III trials

Phase I protocol for ENT-103 being drawn up

New phase II trial evaluates elsamitrucin for refractory NHL

West Nile patient responds to GenoMed treatment

Sangart cleared to commence Swedish phase II trial of Hemospan

CS-917 completes second phase IIa trial

Phase II Pentrix trial set to commence

Cytos' second Immunodrug platform enters clinical development

Gabitril to enter phase III trial in second half of 2004

Expanded Provigil label approved in U.K.

Termination of Ono and Cortech's oral elastase inhibitor agreement

mGluR2 receptor agonists for neurological, psychiatric disorders claimed by Merck

Pfizer patents MMP-12 and MMP-13 inhibitors for treatment of respiratory diseases

C5a receptor modulators in early development at Neurogen

Orchid develops novel oxazolidinone derivatives useful as antibacterial agents

New biphenyl cannabinoids described in patent literature

Novel pyridyl substituted heterocycles for treatment, prevention of HCV

Patent claims method for treatment of osteoarthritis, rheumatoid arthritis, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Sex differences shape gene activity across the human brain
BioWorld
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
Gilead Sciences patents new GTPase KRAS G12D inhibitors
BioWorld Science
Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.